⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTNM News
Contineum Therapeutics, Inc. Class A Common Stock
Form 8-K
sec.gov
CTNM
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
businesswire.com
CTNM
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM
Contineum Therapeutics to Attend the 8 th Annual Evercore Healthcare Conference
businesswire.com
CTNM
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
businesswire.com
CTNM
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
businesswire.com
CTNM
CTNM